DMAC long strategyA analysis of DMAC in a multi-year chart run to see if market downward pressure is substantial enough overshadow the upcoming catalyst for DMAC in the coming weeks.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.62USD
−19.38 MUSD
23.78 M
About DiaMedica Therapeutics Inc.
Sector
CEO
Rick John Pauls
Headquarters
Minneapolis
Website
Employees (FY)
19
Founded
2000
FIGI
BBG000LP4YD7
DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
DMAC price may climb as it breaks lower Bollinger Band on Jul 10This price move could be a signal that DMAC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. Tickeron A.I.dvisor backtested 34 similar cases where DMAC's price broke its lower Bollinger Band, and 33 of them led to a
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of DMAC is 3.36 USD — it has increased by 12.00% in the past 24 hours. Watch DiaMedica Therapeutics Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange DiaMedica Therapeutics Inc. stocks are traded under the ticker DMAC.
DiaMedica Therapeutics Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
DMAC stock is 14.47% volatile and has beta coefficient of 1.72. Track DiaMedica Therapeutics Inc. stock price on the chart and check out the list of the most volatile stocks — is DiaMedica Therapeutics Inc. there?
DMAC earnings for the last quarter are −0.12 USD per share, whereas the estimation was −0.14 USD resulting in a 14.29% surprise. The estimated earnings for the next quarter are −0.16 USD per share. See more details about DiaMedica Therapeutics Inc. earnings.
Yes, you can track DiaMedica Therapeutics Inc. financials in yearly and quarterly reports right on TradingView.
DMAC stock has risen by 30.74% compared to the previous week, the month change is a 13.90% rise, over the last year DiaMedica Therapeutics Inc. has showed a 97.65% increase.
DMAC net income for the last quarter is −5.16 M USD, while the quarter before that showed −4.47 M USD of net income which accounts for −15.43% change. Track more DiaMedica Therapeutics Inc. financial stats to get the full picture.
Today DiaMedica Therapeutics Inc. has the market capitalization of 113.87 M, it has increased by 15.83% over the last week.
No, DMAC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DMAC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DiaMedica Therapeutics Inc. stock right from TradingView charts — choose your broker and connect to your account.
DMAC reached its all-time high on Aug 7, 2012 with the price of 44.94 USD, and its all-time low was 0.81 USD and was reached on Dec 5, 2014. View more price dynamics on DMAC chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
As of May 6, 2024, the company has 19.00 employees. See our rating of the largest employees — is DiaMedica Therapeutics Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So DiaMedica Therapeutics Inc. technincal analysis shows the strong buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating DiaMedica Therapeutics Inc. stock shows the buy signal. See more of DiaMedica Therapeutics Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on DiaMedica Therapeutics Inc. future price: according to them, DMAC price has a max estimate of 8.00 USD and a min estimate of 6.00 USD. Watch DMAC chart and read a more detailed DiaMedica Therapeutics Inc. stock forecast: see what analysts think of DiaMedica Therapeutics Inc. and suggest that you do with its stocks.